Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Bicalutamide in combination with Sunitinib

Antineoplastics, Antiandrogen; CYP3A4 Inhibitor

Trial Locations (1)

RECRUITING

UB/ Great Lakes Cancer Care, Buffalo

All Listed Sponsors

lead

State University of New York at Buffalo

OTHER